JOC*Article*

A New Route to Diverse 1-Azasugars from *N*-Boc-5-hydroxy-3-piperidene as a Common Building Block

Hidekazu Ouchi, Yukiko Mihara, and Hiroki Takahata*

Faculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, Sendai 981-8558, Japan

takahata@tohoku-pharm.ac.jp

A new general method for the synthesis of a variety of 1-azasugars with a nitrogen atom at the anomeric position is described. The readily available chiral *N*-Boc-5-hydroxy-3-piperidene **3** is transformed to isofagomine (**2**), homoisofagomine (**13**), and 5′-deoxyisofagomine (**14**) via stereoselective epoxidation and regioselective ring-cleavage in a highly stereocontrolled manner. In addition, the synthesis of all four stereoisomers of 3,4,5-trihydroxypiperidines (**18−21**) classified as 1-azasugar-type glycosidase inhibitors was stereoselectively achieved from the (chiral) piperidene **3**.

Introduction

Glycosciences are emerging as a key research field at the frontiers of biology, synthetic and supramolecular chemistry, and enzymology.[1] Among the carbohydrate processing enzymes, glycosidases have been identified as an important class of therapeutic targets with applications in the treatment of influenza infection,[2] cancer,[3] AIDS,[4] and diabetes.[5] As a result, numerous classes of inhibitors have been developed, some of which provide interesting insights into the mechanism of enzymatic glycoside hydrolysis. Among them, both naturally occur-

ring and synthetic polyhydroxylated piperidines[6] have been shown to be specific and potent inhibitors of glycosidases[7] and have been demonstrated to have great potential as drugs for treating a variety of carbohydrate-mediated diseases.[8]

The transition states for enzymatic glycosidase hydrolysis have considerable oxocarbenium-ion characteristics, in that the anomeric carbon acquires sp² hybridization and a partial positive charge develops at the anomeric carbon and the endocyclic oxygen.[9] Iminosugars such as 1-deoxynojirimycin (**1**) and isofagomine (**2**), as transition-state analogues, are of particular interest in terms of inhibitor design (Figure 1). A new class of sugar mimic inhibitor having a nitrogen atom at the anomeric position is 1-azasugars such as **2**. These compounds are

(1) (a) Sears, P.; Wong, C.-H. *Science* **2001**, *291*, 2344−2350. (b) Bertozzi, C. R.; Kiessling, L. *Science* **2001**, *291*, 2357−2364.

(2) (a) von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hothman, V. J.; Cameron, J. M.; Penn, C. R. *Nature* **1993**, *363*, 418−423. (b) Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; Stevens, R. C. *J. Am. Chem. Soc.* **1997**, *119*, 681−690. (c) Chand, P.; Kotian, P. L.; Dehghani, A.; El-Kattan, Y.; Lin, T.-H.; Hutchison, T. L.; Sudhakar Babu, Y.; Bantia, S.; Elliott, A. J.; Montgomery, J. A. *J. Med. Chem.* **2001**, *44*, 4379−4392.

(3) (a) Goss, P. E.; Baker, M. A.; Carver, J. P.; Dennis, J. W. *Clin. Cancer Res.* **1995**, *1*, 935−944. (b) Nishimura, Y.; Satoh, T.; Adachi, H.; Kondo, S.; Takeuchi, T.; Azetaka, M.; Fukuyasu, H.; Iizuka, Y. *J. Med. Chem.* **1997**, *40*, 2626−2633. (c) Zitzmann, N.; Mehta, A. S.; Carrouée, S.; Butters, T. D.; Platt, F. M.; McCauley, J.; Blumberg, B. S.; Dwek, R. A.; Block, T. M. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*, 11878−11882.

(4) (a) Karlsson, G. B.; Butters, T. D.; Dwek, R. A.; Platt, F. M. *J. Biol. Chem.* **1993**, *268*, 570−576. (b) Groopman, J. E. *Rev. Infect. Dis.* **1990**, *12*, 931−937.

(5) (a) Treadway, J. L.; Mendys, P.; Hoover, D. J. *Expert Opin. Invest. Drugs* **2001**, *10*, 439−454. (b) Jacob, G. S. *Curr. Opin. Struct. Biol.* **1995**, *5*, 605−611.

(6) (a) Asano, N. *Glycobiology* **2003**, *13*, 93R−104R. (b) Asano, N. *Curr. Top. Med. Chem.* **2003**, *3*, 471−484. (c) Compain, P.; Martin, O. R. *Curr. Top. Med. Chem.* **2003**, *3*, 541−560. (d) Nash, R. J.; Watson, A. A.; Asano, N. In *Alkaloids*: *Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; Elsevier: Oxford, UK, 1996; Vol. 11, pp 345−376. (e) Elbein, A. D.; Molyneux, R. J. In *Comprehensive Natural Products*; Barton, D., Nakanishi, K., Eds.; Elsevier: New York, 1999; Vol. 3, pp 129−160.

(7) (a) Bols, M. *Acc. Chem. Res.* **1998**, *31*, 1. (b) *Iminosugars as Glycosidase Inhibitors. Nojirimicin and Beyond*; Stütz, A. E., Ed.; Wiley-VCH: Weinheim, Germany, 1999.

(8) (a) Somsak, L.; Nagy, V.; Hadady, Z.; Docsa, T.; Gergely, P. *Curr. Pharm. Des.* **2003**, *9*, 1177−1189. (b) Greimel, P.; Spreitz, J.; Stutz, A. E.; Wrodnigg, T. M. *Curr. Top. Med. Chem.* **2003**, *3*, 513−523. (c) Nishimura, Y. *Curr. Top. Med. Chem.* **2003**, *3*, 575−591.

(9) (a) Zechel, D. L.; Boraston, A. B.; Gloster, T.; Boraston, C. M.; MacDonald, J.; Tilbrook, D. M. G.; Stick, R. V.; Davies, G. J. *J. Am. Chem. Soc.* **2003**, *125*, 14313−14323. (b) Zechel, D. L.; Withers, S. G. *Acc. Chem. Res.* **2000**, *33*, 11−18.

FIGURE 1. Transition state for the hydrolysis step of an inverting glycosidase and azasugars.

FIGURE 2. Structures of a common building block **3** and 1-azasugars **4**.

SCHEME 1 [a]

[a] Reagents and conditions: (a) (i) cat. H_2O, 100 °C, (ii) Boc_2O, NaOH; (b) Grubbs' catalyst, CH_2Cl_2, rt.

highly potent inhibitors of β-glycosidases, whose substrates they mimic.[10]

As a consequence, in recent years there has been a great deal of interest not only in the synthesis of the natural products themselves but also in the nature of chemically modified analogues. However, most of the methodologies described for the synthesis of these compounds, which can be regarded as azasugars (also called iminosugars), start from carbohydrates and, in general, require a large number of steps to reach a specific target. Thus, the development of new methods for the enantioselective synthesis of polyhydroxylated piperidines constitutes an area of considerable current interest.[11]

As a part of our ongoing interest in the polyhydroxy piperidines,[12] we envisioned the use of *N*-Boc-5-hydroxy-3-piperidene (**3**) as a general representative chiral building block that might permit easy access to these classes of compounds. This design was surmised keeping in mind the general substitution pattern of the 1-azasugars of **4**.

We report herein a full paper[13] describing the synthesis of both enantiomers of a variety of the 1-azasugars **4** such as isofagomine (**2**) by a general route starting from the (chiral) *N*-Boc-5-hydroxy-3-piperidene (**3**) as depicted in Figure 2.

Results and Discussion

Synthesis of racemic *N*-Boc-5-hydroxy-3-piperidene (**3**) as the starting material began with the regioselective opening of butadiene monoxide with allylamine followed by protection of the secondary amine to afford the metathesis precursor **5** (66%) together with the undesired ring-opening product **6** (20%).[14] The Grubbs' catalyst[15] could be used directly on **5** to afford the ring-closing metathesis product **3** in 99% yield (Scheme 1).

Ogasawara reported[16] on the lipase-catalyzed transesterification of *N*-Cbz-5-hydroxy-3-piperidene with vinyl acetate. We applied this method to **3** using lipase and vinyl acetate. Of the various lipases tested, resolution was best achieved with lipase PS (*Pseudomonas cepacia*), immobilized on ceramic particles, in *tert*-butyl methyl ether at 40 °C, which gave the acetate (−)-**7** in 49% yield, along with the unreacted alcohol (+)-**3**, in 48% yield. In addition, the enzymatic hydrolysis of the acetate (−)-**7** with the same lipase in 0.1 M phosphate buffer afforded the enantiometric alcohol (−)-**3** in 98% yield. The enantiomeric purities of (+)- and (−)-**3** were >99% ee, as determined by chiral HPLC analysis after replacing the *N*-protecting group with Cbz (Scheme 2).

Alcohol (+)-**3** was initially converted into the TBDPS derivative **8**, thus avoiding the possible assistance of the hydroxyl group in the favored approach of the oxidant.

(10) (a) Jespersen, T. M.; Dong, W.; Sierks, M. R.; Skrydstrup, T.; Lundt, I.; Bols, M. *Angew. Chem.*, *Int. Ed. Engl.* **1994**, *33*, 1778−1779. (b) Ichikawa, M.; Igarashi, Y.; Ichikawa, Y. *Tetrahedron Lett.* **1995**, *36*, 1767−1770. (c) Ichikawa, Y.; Igarashi, Y. *Tetrahedron Lett.* **1995**, *36*, 4585−4586. (d) Hansen, A.; Tagmose, T. M.; Bols, M. *Chem. Commun.* **1996**, 2649−2650. (e) Nishimura, Y.; Satoh, T.; Kudo, T.; Kondo, S.; Takeuchi, T. *Bioorg. Med. Chem.* **1996**, *4*, 91−96. (f) Igarashi, Y.; Ichikawa, M.; Ichikawa, Y. *Tetrahedron Lett.* **1996**, *37*, 2707−2708. (g) Igarashi, Y.; Ichikawa, M.; Ichikawa, Y. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 553−558. (h) Bols, M.; Hazell, R. G.; Thomsen, I. B. *Chem. Eur. J.* **1997**, *3*, 940−947. (i) Ichikawa, Y.; Igarashi, Y.; Ichikawa, M.; Suhara, Y. *J. Am. Chem. Soc.* **1998**, *120*, 3007−3018. (j) Nishimura, Y.; Shitara, E.; Adachi, H.; Toyoshima, M.; Nakajima, M.; Okami, Y.; Takeuchi, T. *J. Org. Chem.* **2000**, *65*, 2−11. (k) Shitara, E.; Nishimura, Y.; Kojima, F.; Takeuchi, T. *Bioorg. Med. Chem.* **2000**, *8*, 343−352. (l) Søhoel, H.; Liang, X.; Bols, M. *J. Chem. Soc.*, *Perkin Trans. 1* **2001**, 1584−1585. (m) Jakobsen, P.; Lundbeck, J. M.; Kristiansen, M.; Breinholt, J.; Demuth, H.; Pawlas, J.; Candela, M. P. T.; Andersen, B.; Westergaard, N.; Lundgren, K.; Asano, N. *Bioorg. Med. Chem.* **2001**, *9*, 733−744. (n) Liu, H.; Liang, X.; Søhoel, H. H.; Bülow, A.; Bols, M. *J. Am. Chem. Soc.* **2001**, *123*, 5116−5117.

(11) (a) Kazmaier, U.; Schneider, C. *Tetrahedron Lett.* **1998**, *39*, 817−818. (b) Kim, Y. J.; Ichikawa M.; Ichikawa, Y. *J. Org. Chem.* **2000**, *65*, 2599−2602. (c) Mehta, G.; Mohal, N. *Tetrahedron Lett.* **2000**, *41*, 5747−5751. (d) Liang, X.; Lohse, A.; Bols, M. *J. Org. Chem.* **2000**, *65*, 7432−7437. (e) Pandey, G.; Kapur, M. *Tetrahedron Lett.* **2000**, *41*, 8821−8824. (f) Zhao, G.; Deo, U. C.; Ganem, B. *Org. Lett.* **2001**, *3*, 201−203. (g) Pandey, G.; Kapur, M. *Synthesis* **2001**, 1263−1267. (h) Andersch, J.; Bols, M. *Chem. Eur. J*. **2001**, 7, 3744−3747. (i) Comins, D. L.; Fulp, A. B. *Tetrahedron Lett*. **2001**, *42*, 6839−6841. (j) Best, W. M.; MacDonald, J. M.; Skelton, B. W.; Stick, R. V.; Tilbrook, D. M. G.; White, A. H. *Can. J. Chem.* **2002**, *80*, 857−865. (k) Guanti, G.; Riva, R. *Tetrahedron Lett.* **2003**, *44*, 357−360. (k) Pandey, G.; Kapur, M.; Khan, M. I.; Gaikwad, S. M. *Org. Biomol. Chem.* **2003**, *1*, 3321−3326.

(12) (a) Takahata, H.; Banba, Y.; Sasatani, M.; Nemoto, H.; Kato, A.; Adachi, I. *Tetrahedron* **2004**, *60*, 8199−8205. (b) Takahata, H.; Banba, Y.; Ouchi, H.; Nemoto, H. *Org. Lett.* **2003**, *5*, 2527−2529. (c) Takahata, H.; Banba, Y.; Ouchi, H.; Nemoto, H.; Kato, A.; Adachi, I. *J. Org. Chem.* **2003**, *68*, 3603−3607. (d) Banba, Y.; Abe, C.; Nemoto, H.; Kato, A.; Adachi, I.; Takahata, H. *Tetrahedron*: *Asymmetry* **2001**, *12*, 817−819.

(13) For a preliminary communication of this part of this work, see: Ouchi, H.; Mihara, Y.; Watanabe, H.; Takahata, H. *Tetrahedron Lett.* **2004**, *45*, 7053−7056.

(14) (a) Evans, D. A.; Campos, K. R.; Tedrow, J. S.; Michael, F. E.; Gagné, M. R. *J. Am. Chem. Soc.* **2000**, *122*, 7905−7920. (b) Baker, S. R.; Cases, M.; Keenan, M.; Lewis, R. A.; Tan, P. *Tetrahedron Lett.* **2003**, *44*, 2995−2999. These papers reported the highly regioselective opening took place to provide only **5** as a single product in 52% and 39% yields, respectively.

(15) Grubbs, R. H.; Chang, S. *Tetrahedron* **1998**, *54*, 4413−4450.
(16) Sakagami, H.; Ogasawara, K. *Synthesis* **2000**, 521−524.

SCHEME 2 [a]

(±)-3   (−)-7   49 %   (+)-3   48 %   (−)-3

b   98%

[a] Reagents and conditions: (a) vinyl acetate, lipase PS (immobilized on ceramic particles)/*t*-BuOMe, 40 °C, 18 h; (b) lipase PS (immobilized on ceramic particles)/0.1 M phosphate buffer (pH 7), acetone, 40 °C, 18 h.

SCHEME 3 [a]

(+)-3

99% | a

8   9   72 %   10   17%

[a] Reagents and conditions: (a) TBDPSCl, imidazole, cat. DMAP/ CH₂Cl₂, rt, 3 h; (b) Oxone, aq Na₂EDTA, NaHCO₃, CF₃COCH₃/ CH₃CN, 0 °C, overnight.

Treatment of (+)-**3** with *tert*-butyldiphenylsilyl chloride under basic conditions gave the TBDPS derivative **8** in 99% yield. In an initial experiment, the oxidation of **8** with *m*-CPBA resulted in a low diastereoselectivity to give the anti epoxide **9** and the syn epoxide **10** in 41% and 23% yields, respectively. Subsequently, the use of (trifluoromethyl)methyldioxirane instead of *m*-CPBA as an oxidizing agent improved both the yield and the diastereoselectivity. Thus, the dioxirane, generated in situ[17] from Oxone with 1,1,1-trifluoroacatone, was reacted with **8** to give the anti epoxide **9** and the syn epoxide **10** in 72% and 17% yields, respectively.

In diastereoselective epoxidation of allylically substituted six-membered cyclic alkene, dioxrane can be an oxygen atom to the olefin double bond of substrate from both faces, so there are two possible spiro transition states based on steric considerations.[18] In the favored TS leading to anti epoxide **9**, there are little interactions between the R₁ and the allylic hydrogen of substrate. On the other hand, severe steric interaction between the R₁ and the allylic large OTBDPS group is expected in the disfavored TS leading to syn epoxide **10**. Therefore, it appears that an attack on the dioxirane preferably occurred preferentially at the less hindered anti side to the large OTBDPS group (Scheme 4).

The nucleophilic opening of the anti epoxide **9** with "higher order" cuprate[19] free halide ions in the presence of boron trifluoride etherate as the activating species was carried out as follows: treatment of **9** with (CH₂=CH)₂-

SCHEME 4. Stereochemistry of the Epoxidation of 8

favored TS   disfavored TS

R₁, R₂ = CF₃ or CH₃

9   10

SCHEME 5. Regiochemistry of the Nucleophilic Opening of the Epoxide 9

Conformer **A**   Conformer **B**

C-5 Product   C-4 Product

CuCNLi₂ in the presence of BF₃·OEt₂ at −78 °C for 2 h gave **11** as the sole isolable product in 74% yield. Analogously, the reaction of **9** with Me₂CuCNLi₂ afforded only **12** in 71% yield. An attempt to employ Grignard reagents in the presence of cuprous bromide[20] resulted in no reaction. Although the rationale for this high selectivity remains unclear, the following mechanism is consistent with the results. The regiochemistry of the nucleophilic opening of the epoxide on a six-membered ring is mainly subject to trans diaxial opening (Fürst–Plattner rule).[21] Consequently, a high regioselectivity would result if the opening proceeded through only one of the two possible half-chair conformations (**A** and **B**). Thus, the exclusive attack of the nucleophile at C-5 through conformer **A** would occur with trans diaxial opening. On the other hand, an attack of a nucleophile at C-4 of **9** through conformer **B** would be subject to steric hindrance by the pseudoequatorial OTBDPS group at C-3. Therefore, a trans diaxial opening through one of the half-chair conformers, namely conformer **A**, would occur (Scheme 5). A similar regioselectivity has been reported for ring-opening reactions of *trans*-3-(benzyloxy)-1,2-epoxycyclohexane derivatives.[22]

With the vinyl product **11** in hand, our interest was directed to its conversion to isofagomine (**2**) and homo-

(17) Yang, D.; Wong, M.-K.; Yip, Y.-C. *J. Org. Chem.* **1995**, *60*, 3887–3889.

(18) (a) Murray, R. W.; Singh, M.; Williams, B. L.; Moncrieff, H. M. *J. Org. Chem.* **1996**, *61*, 1830–1841. (b) Yang, D.; Jiao, G.-S.; Yip, Y.-C.; Wong, M.-K. *J. Org. Chem.* **1999**, *64*, 1635–1639.

(19) Review: Lipshutz, B. H.; Wilhelm, R. S.; Kozlowski, J. A. *Tetrahedron* **1984**, *40*, 5005–5038.

(20) (a) Tius, M. A.; Fauq, A. H. *J. Org. Chem.* **1983**, *48*, 4131–4132. (b) Roush, W. R.; Adam, M. A.; Walts, A. E.; Harris, D. J. *J. Am. Chem. Soc.* **1986**, *108*, 3422–3434.

(21) Eliel, E. L.; Wilen, S. H. *Stereochemistry of Organic Compounds*; Wiley-Interscience: New York, 1994; p 730.

(22) (a) Crotti, P.; Renzi, G.; Favero, L.; Roselli, G.; Bussolo, V. D.; Caselli, M. *Tetrahedron* **2003**, *59*, 1453–1467. (b) Crotti, P.; Bussolo, V. D.; Favero, L.; Macchia, F.; Renzi, G.; Roselli, G. *Tetrahedron* **2002**, *58*, 7119–7133. (c) Crotti, P.; Bussolo, V. D.; Favero, L.; Pineschi, M.; Marianucci, F.; Renzi, G.; Amici, G.; Roselli, G. *Tetrahedron* **2000**, *56*, 7513–7524. (d) Calvani, F.; Crotti, P.; Gardelli, C.; Pineschi, M. *Tetrahedron* **1994**, *50*, 12999–13022. (e) Chini, M.; Crotti, P.; Gardelli, C.; Macchia, F. *J. Org. Chem.* **1994**, *59*, 4131–4137. (f) Montchamp, J.-L.; Migaud, M. E.; Frost, W. *J. Org. Chem.* **1993**, *58*, 7679–7684.

SCHEME 6 [a]

9 — **a** 74% → [structure: TBDPSO, OH, vinyl, Boc]

11 — **d** 88% →

71% **b** ↓

c 85% → **2**

12 [structure: TBDPSO, OH, CH₃, Boc]

e 92% → **14** [structure: HO, OH, CH₃, NH]

13 [structure: HO, OH, CH₂CH₂OH, NH]

[a] Reagents and conditions: (a) (CH$_2$=CH)$_2$CuCNLi$_2$ (5 equiv), BF$_3$·OEt$_2$ (2 equiv)/Et$_2$O, −78 °C, 2 h; (b) Me$_2$CuCNLi$_2$ (5 equiv), BF$_3$·OEt$_2$ (2 equiv),/Et$_2$O, −78 °C; (c) (i) cat. OsO$_4$, NaIO$_4$/50% EtOH, rt, overnight, (ii) NaBH$_4$/50% EtOH, rt, 1 h, (iii) 10% HCl/dioxane, reflux, 1 h; (d) (i) 9-BBN/THF, rt, 6 h, (ii) H$_2$O$_2$, 3 mol/L of NaOH/THF, rt, 1 h, (iii) 10% HCl/dioxane, reflux, 1 h; (e) 10% HCl/dioxane, reflux, 1 h.

15
48.6% overall yield from (−)-**3**

16
50.3% overall yield from (−)-**3**

17
46.5% overall yield from (−)-**3**

FIGURE 3. Structures of the enantiomers of **2**, **13**, and **14**,

18   **19**   **20**

FIGURE 4. Structures of three 3,4,5-trihydroxypiperidines isolated from *Eupatorium fortunei* TURZ.

isofagomine (**13**). Oxidative cleavage of the vinyl group of **11** with OsO$_4$ and NaIO$_4$ afforded the aldehyde, which without purification, and after reduction with NaBH$_4$ followed by deprotection, afforded isofagomine (**2**) in 85% combined yield. The optical rotation and spectral characteristics of **2** were in good agreement with those reported in the literature.[11g] Next, the hydroboration of the vinyl group of **11** with 9-BBN followed by treatment with hydrogen peroxide gave the corresponding primary alcohol. Deprotection of the alcohol with 10% HCl in 1,4-dioxane afforded **13** in 86% combined yield. Conversion of **12** to 5′-deoxyisofagomine (**14**) was accomplished by deprotection. The complete deprotection of **12** by treatment with 10% HCl in 1,4-dioxane afforded **14** in 92% yield. Thus the first synthesis of **13** and **14** was achieved (Scheme 6).

Enantiomers of **2**, **13**, **14**, and **15**−**17** were also prepared starting from (−)-**3**, following the same procedure as above (Figure 3).

The above successes led us to consider the synthesis of some of the most important 3,4,5-piperidine triols, namely, **18**, **19**, and **20** (Figure 4). These trihydroxy piperidines are regarded as derivatives of their parent deoxynojirimycin and have been shown to possess moderate to good glycosidase inhibitory activity. A careful

SCHEME 7 [a]

ent-**8** — **a** →

22 [structure with OH, HO, OH, Boc]
74%

+ **23**
3%

b 98% →

18   **21**

[a] Reagents and conditions: (a) (i) cat. OsO$_4$, NMO, acetone, (ii) TBAF, THF, rt; (b) (i) 10% HCl, dioxane, reflux, (ii) Amberlite IRA-410.

consideration of these structural moieties reveals that these molecules can also be classified as 1-*N*-iminosugar-type glycosidase inhibitors, although they do not resemble any of the presently known pyranose sugars.

Triols **18**, **19**, and **20** were isolated from *Eupatorium fortunei* TURZ by Kusano and co-workers[23] in 1995 and have been shown to be the active components of the extracts of this plant, which are traditionally used in Chinese and Japanese folk medicine as a diuretic, antipyretic, emmenagogue, and antidiabetic agent. Triols **18**−**20** have also been synthesized by Ganem[24] and others[25] and have been shown to be good selective inhibitors of glycosidases.

We realized that our precursors (+)-, (−)-, and (±)-**3** would be ideal candidates for the synthesis of these molecules together with the enantiomer of **18**, **21**. The synthesis of des(hydroxymethyl)deoxymannojirimycin (**18**) commenced with *ent*-**8**, which was previously synthesized from (−)-**3**. The stereoselective dihydroxylation of the double bond was also examined. Treatment of *ent*-**8** with a catalytic amount of OsO$_4$ (5 mol %) and 4-methylmorphorine *N*-oxide as a cooxidant[26] gave an inseparable mixture of diastereomeric diols, which was subjected to treatment with TBAF to provide the triol **22** as a major product along with minor amounts of triol **23**. This high diastereoselectivity in the dihydroxylation step can be attributed to the a steric blocking of an allylic *O*-TBDPS substituent.[25h] Deprotection of **22** with HCl in dioxane followed by treatment with an ion-exchange resin (Amberlite IRA-410 OH$^-$ form) afforded **18** in 98% combined yield. In a similar procedure, the enantiomer **21** was prepared from (+)-**3** in 69% yield (Scheme 7). The spectral data and optical rotation for **18** and **21** were found to be in good agreement with reported values from the literature.[23,25c] Donohoe reported[27] that osmium tetroxide produces a bidendate and reactive complex with TMEDA, which can be used to achieve the directed

(23) Sekioka, T.; Shibano, M.; Kusano, G. *Nat. Med.* (*Tokyo, Jpn.*) **1995**, *49*, 332−335.

(24) Bernotas, R. C.; Papandreou, G.; Urbach, J.; Ganem, B. *Tetrahedron Lett.* **1990**, *31*, 3393−3396.

(25) (a) Tschamber, T.; Backenstrass, F.; Neuburger, M.; Zehnder, M.; Streith, J. *Tetrahedron* **1994**, *50*, 1135−1152. (b) Legler, G.; Stütz, A. E.; Immich, H. *Carbohydr. Res.* **1995**, *272*, 17−30. (c) Godskesen, M.; Lundt, I.; Madsen, R.; Winchester, B. *Bioorg. Med. Chem.* **1996**, *4*, 1857−1865. (d) Sames, D.; Polt, R. *Synlett* **1995**, 552−554. (e) Amat, M.; Llor, N.; Huguet, M.; Molins, E.; Espinosa, E.; Bosch, J. *Org. Lett.* **2001**, *3*, 3257−3260. (f) Patil, N. T.; John, S.; Sabharwal, S. G.; Dhawale, D. D. *Bioorg. Med. Chem.* **2002**, *10*, 2155−2160. (g) Pandey, G.; Kapur, M. *Org. Lett.* **2002**, *4*, 3883−3886. (h) Han, H. *Tetrahedron Lett.* **2003**, *44*, 1567−1569. In this paper, a highly stereocontrolled synthesis of **18** and **20** as hydrochloride salts from the *O*-MOM protected piperidene of **3** has been reported. (i) Pandey, G.; Kapur, M.; Khan, M. S.; Gaikwad, S. M. *Org. Biomol. Chem.* **2003**, *1*, 3321−3326.

(26) VanRheenen, V.; Kelly, R. C.; Cha, D. Y. *Tetrahedron Lett.* **1976**, *17*, 1973−1976.

SCHEME 8 [a]

[a] Reagents and conditions: (a) (i) OsO$_4$,TMEDA, CH$_2$Cl$_2$, −78 °C, (ii) conc HCl, MeOH, rt, (iii) Boc$_2$O, Et$_3$N, MeOH; (b) (i) 10% HCl, dioxane, reflux, (ii) Amberlite IRA-410; (c) (i) 10% H$_2$SO$_4$, dioxane, 95 °C, 3 h, (ii) Amberlite IRA-410.

dihydroxylation of cyclic allylic alcohols. Under this condition, hydrogen bonding control leads to the formation of the syn isomer in almost every case. Therefore, the oxidation of (±)-**3** with a combination of OsO$_4$ with TMEDA gave the *all-cis*-triol **23** and (±)-**22** in moderate selectivity (4:1) in 66% and 16% yields, respectively. Finally, removal of the Boc group from **23**, followed by ion-exchange chromatographic purification yielded **19** in 94% yield, the spectral data for which were in excellent agreement with data reported in the literature. Next, the anti epoxide (±)-**9** obtained from (±)-**8** according to the same procedure for the preparation of (+)-**9** was hydrolyzed with 10% H$_2$SO$_4$ in dioxane to afford the triol **20** as a major product and (±)-**18** as a minor one in 55% and 20% yields, respectively. This moderate diastereoselectivity compared with the high selectivity of nucleophilic cleavage of **9** with vinylmetal may be due to the following reason. Because partial desilylation prior to ring opening of epoxide in acidic condition can occur, the steric hindrance between nucleophile (H$_2$O) and allylic hydroxy substituent in analogous conformer **B** described in Scheme 5 would diminish.

Summary

An efficient synthesis of isofagomine (**2**), homoisofagomine (**13**), 5-deoxyisofagomine (**14**), and their enantiomers **15**−**17** with a nitrogen atom at the anomeric position was achieved in 44−50% overall yields from the readily obtainable chiral *N*-Boc-5-hydroxy-3-piperidene (**3**). The reaction involved the epoxidation into a double bond and a regioselective epoxide ring opening reaction with higher ordered cuprates. To our knowledge our route to isofagomine (**2**) is shorter and more efficient than the other reported syntheses.[10] In addition, the stereoselective synthesis of all four of the stereoisomers of 3,4,5-trihydroxypiperidines (**18**−**21**) was achieved from the common building block **3**. This synthetic route permits the preparation of substantial amounts of 1-azasugars having a glucose configuration and would be suitable for

(27) (a) Donohoe, T. J.; Blades, K.; Moore, P. R.; Waring, M. J.; Winter, J. J. G.; Helliwell, M.; Newcombe, Ni. J.; Stemp, G. *J. Org. Chem.* **2002**, *67*, 7946−7956. (b) Donohoe, T. J. *Synlett* **2002**, 1223−1232.

further studies of such compounds as glycosidase inhibitors.

Experimental Section

***tert*-Butyl *N*-Allyl-*N*-(2-hydroxy-3-butenyl)carbamate (5) and *tert*-Butyl Allyl-1-hydroxybut-3-enylcarbamate (6).** To a solution of allylamine (8.5 mL, 20 mmol) and water (530 μL) was added butadiene monoxide (3.0 mL, 37.5 mmol) at 15 °C. The mixture was warmed to 100 °C and stirred for 6 h. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in dioxane (50 mL) and water (10 mL), 1 mol/L of NaOH (40 mL, 40 mmol), and (Boc)$_2$O (8.37 g, 40 mmol) were added. The mixture was stirred at room temperature overnight. The residue obtained after evaporation was taken up in Et$_2$O (200 mL), and washed with water (100 mL), 20% citric acid (100 mL), and brine (100 mL). The combined aqueous solutions were extracted with Et$_2$O (2 × 50 mL). The combined organic solutions were dried over MgSO$_4$, filtered, concentrated in vacuo, and purified by flash column chromatography on silica gel (*n*-hexane:AcOEt = 4:1−1:1) to give **5** (5.62 g, 66%) as a colorless oil and **6** (1.68 g, 20%) as a colorless oil.

5: ^{1}H NMR (600 MHz, CDCl$_3$) δ 1.44 (s, 9H), 3.26 (br s, 1H), 3.31 (br s, 1H), 3.66 (br s, 1H), 3.74−3.94 (m, 2H), 4.29−4.32 (m, 1H), 5.09−5.15 (m, 3H), 5.32 (d, *J* = 16.5 Hz, 1H), 5.66−5.84 (m, 2H). ^{13}C NMR (100 MHz, CDCl$_3$) δ 28.3, 51.7, 53.4, 72.7, 80.4, 115.7, 116.4, 133.8, 138.4, 157.6. IR (neat) (cm^{-1}) 3432, 1675. EI-MS (*m/z*) 228 (M$^+$ + 1). HRMS calcd for C$_{10}$H$_{17}$NO$_3$ 227.1521, found 227.1538. Anal. Calcd for C$_{12}$H$_{21}$-NO$_3$: C, 63.41; H, 9.31; N, 6.16. Found: C, 63.10; H, 9.52; N, 6.28.

6: ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.46 (s, 9H), 2.27−3.00 (br, 1H), 3.77 (br d, *J* = 7.1 Hz, 4H), 4.38 (br d, *J* = 5.6 Hz, 1H), 5.06−5.26 (m, 4H), 5.74−5.96 (m, 2H). ^{13}C NMR (100 MHz, CDCl$_3$) δ 28.4, 48.3, 61.1, 63.6, 80.3, 117.5, 134.0, 135.3, 156.3. IR (neat) (cm^{-1}) 3436, 1694. EI-MS (*m/z*) 228 (M$^+$ + 1). HRMS calcd for C$_{12}$H$_{21}$NO$_3$ 227.1521, found 227.1546.

(±)-*N*-*tert*-Butoxycarbonyl-5-hydroxy-3-piperidene ((±)-3). To a deoxygenated solution of **5** (4.54 g, 20 mmol) in CH$_2$-Cl$_2$ (340 mL) under argon atmosphere was added bis-(tricyclohexylphosphine)benzylidine ruthenium(IV) dichloride (0.58 g, 0.71 mmol, 5 mol %). The solution was stirred at room temperature overnight, then concentrated under reduced pressure, and the residue was purified by flash column chromatography on silica gel (*n*-hexane:AcOEt = 2:1) to give (±)-**3** (3.95 g, 99%) as colorless prisms; mp 55−56 °C (*n*-hexane). ^{1}H NMR (600 MHz, CDCl$_3$) δ 1.47 (s, 9H), 1.64 (br s, 1H), 3.53 (br s, 1H), 3.58 (br s, 1H), 3.80 (dd, *J* = 18.7, 2.2 Hz, 1H), 3.97 (br s, 1H), 4.19 (br s, 1H), 5.84 (br s, 1H), 5.89−5.93 (m, 1H). ^{13}C NMR (67.8 MHz, CDCl$_3$) δ 28.4, 43.3, 47.7, 63.6, 80.1, 126.9, 128.3, 155.0. IR (KBr) (cm^{-1}) 3255, 1699. EI-MS (*m/z*) 199 (M$^+$). HRMS calcd for C$_{10}$H$_{17}$NO$_3$ 199.1169, found 199.1208. Anal. Calcd for C$_{10}$H$_{17}$NO$_3$: C, 60.28; H, 8.60; N, 7.03. Found: C, 60.46; H, 8.50; N, 6.87.

(S)-*N*-*tert*-Butoxycarbonyl-5-hydroxy-3-piperidene ((+)-3) and (R)-*N*-*tert*-Butoxycarbonyl-5-acetoxy-3-piperidene ((−)-7). A mixture of (±)-**3** (1.99 g, 10 mmol) and vinyl acetate (4.3 g, 50 mmol) in *tert*-butyl methyl ether (100 mL) was stirred with lipase (1 g, immobilized on Ceramic particles from *Psedomonas cepacia*) at 40 °C for 18 h. After filtration, the filtrate was evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give acetate (−)-**7** (1.18 g, 49%) as a colorless oil from the *n*-hexane/AcOEt (3:1) fraction and the alcohol (+)-**3** (0.96 g, 48%) as colorless needles from the *n*-hexane/AcOEt (1:1) fraction.

(+)-**3**: mp 70−71 °C (*n*-hexane). [α]^{32}$_D$ +83.7 (*c* 1.08, CHCl$_3$).

(−)-**7**: [α]^{30}$_D$ −110.4 (*c* 2.20, CHCl$_3$). ^{1}H NMR (600 MHz, CDCl$_3$) δ 1.46 (s, 9H), 2.05 (s, 3H), 3.47 (dd, *J* = 13.9, 3.7 Hz, 1 H), 3.76 (d, *J* = 19.4, 1H), 3.76 (dd, *J* = 13.9, 4.0 Hz, 1H), 4.12 (m, 1H), 5.15 (br s, 1H), 5.85−5.97 (m, 2H). ^{13}C NMR (67.8

MHz, CDCl$_3$) δ 21.1, 28.4, 42.8, 44.9, 65.7, 79.9, 123.7, 130.4, 154.5, 170.3. IR (neat) (cm^{-1}) 1740, 1700. EI-MS (*m/z*) 242 (M$^+$ + 1). HRMS calcd for C$_{12}$H$_{19}$NO$_4$ 241.1314, found 241.1321.

(*R*)-*N*-*tert*-Butoxycarbonyl-5-hydroxy-3-piperidene ((−)-3). A mixture of acetate (−)-**7** (1.1 g, 4.5 mmol) and acetone (3.14 mL) in phosphate buffer (0.1 mol/L, pH 7.0, 51 mL) was stirred with lipase (0.46 g, immobilized on Ceramic particles from *Psedomonas cepacia*) at 40 °C for 18 h. After filtration, the filtrate was extracted with AcOEt (3 × 50 mL). The combined organic extracts were washed with brine (50 mL), dried over MgSO$_4$, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (*n*-hexane:AcOEt = 1:1) to give (−)-**3** (0.88 g, 98%) as colorless needles; mp 71−72 °C (*n*-hexane). [α]^{30}$_D$ −83.3 (*c* 1.10, CHCl$_3$).

(*S*)-*N*-*tert*-Butoxycarbonyl-5-(*tert*-butyldiphenylsilyloxy)-3-piperidene (8). To a solution of (+)-**3** (996 mg, 5 mmol) in CH$_2$Cl$_2$ (10 mL) was added imidazole (511 mg, 7.5 mmol), DMAP (122 mg, 1 mmol), and *tert*-butylchlorodiphenylsilane (1.512 g, 5.5 mmol). The mixture was stirred at room temperature for 3 h. The reaction mixture was filtered through a Celite pad. The filtrate was washed with brine (10 mL), dried over MgSO$_4$, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (*n*-hexane:AcOEt = 8:1) to give **8** (2.35 g, 99%) as a colorless oil; [α]^{27}$_D$ +22.6 (*c* 1.80, CHCl$_3$). ^{1}H NMR (600 MHz, CDCl$_3$) δ 1.08 (s, 9H), 1.40 (s, 9H), 3.21 (br s, 1H), 3.62−3.96 (m, 3H), 4.25 (br s, 1H), 5.58−5.72 (m, 2H), 7.36−7.44 (m, 6H), 7.67−7.70 (m, 4H). ^{13}C NMR (67.8 MHz, CDCl$_3$) δ 19.2, 26.9, 28.4, 42.7, 47.9, 65.1, 79.5, 126.0, 127.4, 129.2, 129.5, 133.7, 135.5, 154.4. IR (neat) (cm^{-1}) 1703. EI-MS (*m/z*) 438 (M$^+$ + 1). HRMS calcd for C$_{26}$H$_{35}$NO$_3$Si 437.2386, found 437.2448. Anal. Calcd for C$_{26}$H$_{35}$NO$_3$Si: C, 71.35; H, 8.06; N, 3.20. Found: C, 71.16; H, 7.96; N, 3.23.

(3*R*,4*R*,5*R*)-*N*-*tert*-Butoxycarbonyl-3-(*tert*-butyldiphenylsilyloxy)-4,5-epoxypiperidine (9) and (3*R*,4*S*,5*S*)-*N*-*tert*-Butoxycarbonyl-3-(*tert*-butyldiphenylsilyloxy)-4,5-epoxypiperidine (10). To a cooled (0 °C) solution of **8** (945 mg, 2.16 mmol) in CH$_3$CN (20 mL) was added 4 mmol/L of aq Na$_2$EDTA (10 mL, 0.04 mmol) and 1,1,1-trifluoroacetone (2 mL). The mixture of NaHCO$_3$ (1.26 g, 15 mmol) and Oxone (6.13 g, 10 mmol) as a solid was added slowly over a period of 1 h at 0 °C. After being stirred at 0 °C overnight, the solution was quenched by adding water (60 mL) and extracted with CHCl$_3$ (3 × 60 mL). The organic extracts were combined, dried over MgSO$_4$, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (*n*-hexane:AcOEt = 8:1) to give **9** (706 mg, 72%) as colorless prisms and **10** (170 mg, 17%) as colorless needles.

9: mp 70−72 °C (*n*-pentane); [α]^{30}$_D$ +29.2 (*c* 1.11, CHCl$_3$). ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.10 (s, 9H), 1.37 and 1.46 (2 s, 9H), 3.07−3.41 (m, 4H), 3.07−3.88 (m, 2H), 4.09−4.15 (m, 1H), 7.36−7.45 (m, 6H), 7.63−7.69 (m, 4H). ^{13}C NMR (67.8 MHz, CDCl$_3$) δ 19.3, 27.0, 28.4, 41.4, 45.3, 50.6, 53.7, 65.2, 79.8, 127.7, 129.8, 133.1, 135.5, 154.9. IR (KBr) (cm^{-1}) 1701. EI-MS (*m/z*) 453 (M$^+$). HRMS calcd for C$_{26}$H$_{35}$NO$_4$Si 453.2336, found 453.2343. Anal. Calcd for C$_{26}$H$_{35}$NO$_4$Si: C, 68.84; H, 7.78; N, 3.09. Found: C, 69.03; H, 7.64; N, 2.93.

10: mp 110−111 °C (*n*-pentane); [α]^{26}$_D$ −6.2 (*c* 0.80, CHCl$_3$). ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.09 (s, 9H), 1.35 (s, 9H), 2.87 (br t, *J* = 10.7 Hz, 1H), 3.09 (br s, 1H), 3.20−3.40 (m, 2H), 3.75 (br s, 1H), 3.99−4.03 (m, 2H), 7.37−7.46 (m, 6H), 7.67−7.74 (m, 4H). ^{13}C NMR (67.8 MHz, CDCl$_3$) δ 19.3, 27.0, 28.3, 40.6, 43.1, 53.3, 54.6, 67.5, 79.9, 127.7, 129.8, 133.1, 135.6, 154.0. IR (KBr) (cm^{-1}) 1698. EI-MS (*m/z*) 454 (M$^+$ + 1). HRMS calcd for C$_{26}$H$_{35}$NO$_4$Si 453.2336, found 453.2351. Anal. Calcd for C$_{26}$H$_{35}$NO$_4$Si: C, 68.84; H, 7.78; N, 3.09. Found: C, 68.96; H, 7.88; N, 3.12.

(3*R*,4*R*,5*S*)-*N*-*tert*-Butoxycarbonyl-3-(*tert*-butyldiphenylsilyloxy)-4-hydroxy-5-vinylpiperidine (11). A solution of *n*-BuLi (3.125 mL, 1.6 M in *n*-hexane, 5 mmol) was

added to a solution of tetravinyltin (1.14 g, 5 mmol) in Et$_2$O (7 mL) at room temperature and the mixture was stirred for 1 h at the same temperature. The solution was added to a suspension of CuCN (224 mg, 2.5 mmol) in dry Et$_2$O (20 mL) at −78 °C and the mixture was stirred under argon atmosphere at −78 °C for 10 min. The resulting solution was warmed to −10 °C and stirred for 30 min. The reaction mixture was cooled to −78 °C and a solution of **9** (454 mg, 1 mmol) in dry Et$_2$O (20 mL) was added to the reaction mixture dropwise via syringe at −78 °C. The mixture was stirred at −78 °C for 10 min. BF$_3$·OEt$_2$ (4 mol/L in Et$_2$O, 5 mL, 2 mmol) was added to the reaction mixture at −78 °C and the solution was stirred for 2 h. The reaction mixture was quenched with 28% NH$_4$-OH/sat. NH$_4$Cl (1:9) solution (50 mL) and stirred overnight at room temperature. The organic layer was separated and the aqueous layer was extracted with Et$_2$O (2 × 20 mL). The combined organic phases were washed with brine (20 mL), dried over MgSO$_4$, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (*n*-hexane:AcOEt = 8:1) to give **11** (357 mg, 74%) as a colorless oil; [α]^{24}$_D$ −10.5 (*c* 1.16, CHCl$_3$). ^{1}H NMR (600 MHz, CDCl$_3$) δ 1.09 (s, 9H), 1.31 (s, 9H), 2.12 (br s, 1H), 2.23 (br s, 1H), 2.50 (br s, 1H), 2.65 (dd, *J* = 11.0, 12.5 Hz, 1H), 3.42 (t, *J* = 9.0 Hz, 1H), 3.51−3.55 (m, 1H), 3.82−4.23 (m, 2H), 5.16−5.20 (m, 2H), 5.66−5.72 (m, 1H), 7.38−7.45 (m, 6H), 7.68−7.71 (m, 4H). ^{13}C NMR (67.8 MHz, CDCl$_3$) δ 19.4, 27.0, 28.3, 45.8, 46.5, 48.7, 73.6, 77.7, 79.8, 117.7, 127.7, 129.8, 133.3, 135.7, 135.9, 154.0. IR (neat) (cm^{-1}) 3472, 1698. EI-MS (*m/z*) 482 (M$^+$ + 1). HRMS calcd for C$_{28}$H$_{39}$NO$_4$Si 481.2649, found 481.2686. Anal. Calcd for C$_{28}$H$_{39}$NO$_4$Si: C, 69.82; H, 8.16; N, 2.91. Found: C, 70.10; H, 8.07; N, 2.77.

(3*R*,4*R*,5*R*)-3,4-Dihydroxy-5-(hydroxymethyl)piperidine (2, isofagomine). To a solution of **11** (193 mg, 0.4 mmol) in EtOH (4 mL) and H$_2$O (4 mL) was added an aqueous solution of 4% OsO$_4$ (131 μL, 0.02 mmol) and the solution was stirred at room temperature for 10 min. NaIO$_4$ (190 mg, 0.88 mmol) as a powder was added slowly over a period of 30 min, and the mixture was stirred at room temperature for 24 h. NaBH$_4$ (76 mg, 2 mmol) as a powder was added, and the reaction mixture was stirred at room temperature for 1 h. The solvent was removed in vacuo. The residue was diluted with CHCl$_3$ (80 mL) and successively washed with 10% Na$_2$S$_2$O$_3$ (20 mL), sat. NaHCO$_3$ (20 mL), and brine (10 mL). The organic solution was dried over MgSO$_4$, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (*n*-hexane:AcOEt = 1:1) to give (3*R*,4*R*,5*R*)-*N*-*tert*-butyldiphenylsilyloxy)-4-hydroxy-5-(hydroxymethyl)piperidine (167 mg, 86%) as a colorless oil; [α]^{25}$_D$ −15.9 (*c* 1.35, CHCl$_3$). ^{1}H NMR (600 MHz, CDCl$_3$) δ 1.09 (s, 9H), 1.31 (s, 9H), 1.66 (br s, 1H), 2.48 (br s, 3H), 2.63 (t, *J* = 11.0 Hz, 1H), 3.48−3.56 (m, 2H), 3.67 (s, 2H), 3.85−4.16 (m, 2H), 7.39−7.46 (m, 6H), 7.67−7.69 (m, 4H). ^{13}C NMR (67.8 MHz, CDCl$_3$) δ 19.4, 27.0, 28.3, 42.8, 43.9, 48.5, 63.2, 73.6, 77.7, 79.9, 127.8, 129.9, 133.3, 135.5, 154.2. IR (neat) (cm^{-1}) 3420, 1696, 1674. EI-MS (*m/z*) 486 (M + H$^+$). HRMS calcd for C$_{27}$H$_{39}$NO$_5$Si 485.2598, found 485.2585. To a solution of the prepared diol (160 mg, 0.33 mmol) in dioxane (2.5 mL) was added a solution of 10% HCl (10 mL), and the solution was refluxed for 1 h. After the reaction mixture was cooled to room temperature and diluted with H$_2$O (50 mL), the resulting dilute solution was washed with Et$_2$O (2 × 20 mL). The aqueous layer was concentrated under reduced pressure. The residue was dissolved in 28% NH$_4$OH and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (28% NH$_4$OH:EtOH = 1:10) to give **2** (48.5 mg, 99%) as a white powder; [α]^{25}$_D$ +25.4 (*c* 1.30, EtOH). ^{1}H NMR (600 MHz, D$_2$O) δ 1.61−1.68 (m, 1H), 2.33−2.38 (m, 2H), 3.05 (dd, *J* = 13.0, 3.5 Hz, 1H), 3.10 (dd, *J* = 12.1, 4.8 Hz, 1H), 3.27 (t, *J* = 9.9 Hz, 1H), 3.43−3.48 (m, 1H), 3.59 (dd, *J* = 11.4, 7.0 Hz, 1H), 3.78 (dd, *J* = 11.4, 3.3 Hz, 1H). ^{13}C NMR (67.8 MHz, D$_2$O) δ 43.9, 45.7, 48.8, 59.8, 71.4,

73.1. EI-MS (*m/z*) 147 (M⁺). HRMS calcd for C₆H₁₃NO₃ 147.0895, found 147.0845.

(3R,4R,5S)-3,4-Dihydroxy-5-(hydroxyethyl)piperidine (13, homoisofagomine). To a cooled (0 °C) solution of **11** (96 mg, 0.2 mmol) in THF (3 mL) was added a solution of 9-BBN (0.5 mol/L in THF, 2 mL, 1 mmol). The mixture was warmed to room temperature and stirred for 6 h. The reaction mixture was then cooled to 0 °C. To this solution was added 3 mol/L of NaOH solution (1 mL) and 30% H₂O₂ solution (1 mL). The mixture was stirred at room temperature for 1 h. A sat. NH₄Cl solution (3 mL) was added, and the mixture was extracted with AcOEt (3 × 20 mL). The organic extracts were combined, dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (*n*-hexane:AcOEt = 1:1) to give (3*R*,4*R*,5*S*)-*N*-*tert*-butoxycarbonyl-3-(*tert*-butyldiphenylsilyloxy)-4-hydroxy-5-(hydroxyethyl)piperidine (93 mg, 93%) as a colorless oil; [α]²⁵_D −4.97 (*c* 1.30, CHCl₃). ¹H NMR (600 MHz, CDCl₃) δ 1.08 (s, 9H), 1.29 (br s, 9H), 1.47−1.75 (m, 4H), 2.37 (br s, 1H), 2.61 (t, *J* = 11.7 Hz, 1H), 2.94 (br s, 1H), 3.33 (t, *J* = 9.0 Hz, 1H), 3.47−3.51 (m, 1H), 3.59−3.63 (m, 1H), 3.69−3.73 (m, 1H), 3.84−4.20 (m, 2H), 7.38−7.51 (m, 6H), 7.66−7.69 (m, 4H). IR (neat) (cm⁻¹) 3323, 1697, 1673. EI-MS (*m/z*) 499 (M⁺). HRMS calcd for C₂₈H₄₁NO₅Si 499.2754, found 499.2740. To a solution of the above diol (180 mg, 0.36 mmol) in dioxane (2.5 mL) was added a solution of 10% HCl (10 mL), and the solution was heated at reflux for 1 h. After the reaction mixture was cooled to room temperature and diluted with H₂O (50 mL), the resulting dilute solution was washed with Et₂O (2 × 20 mL). The aqueous layer was concentrated under reduced pressure. The residue was dissolved in MeOH and made alkaline with Na₂CO₃. The mixture was filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (10% NH₄OH:MeOH = 1:50) to give **13** (55 mg, 95%) as a white powder; [α]²⁰_D +17.70 (*c* 1.10, EtOH). ¹H NMR (600 MHz, D₂O) δ 1.22−1.28 (m, 1H), 1.36−1.43 (m, 1H), 1.76−1.82 (m, 1H), 2.11 (dd, *J* = 12.8, 11.7 Hz, 1H), 2.23 (dd, *J* = 12.3, 10.8 Hz, 1H), 2.87 (ddd, *J* = 13.0, 4.2, 1.5 Hz, 1H), 2.94−3.01 (m, 2H), 3.27−3.32 (m, 1H), 3.46−3.55 (m, 2H). ¹³C NMR (67.8 MHz, D₂O) δ 76.5, 71.3, 58.8, 48.8, 47.6, 39.1, 30.7. IR (neat) (cm⁻¹) 3324, 1697, 1674. EI-MS (*m/z*) 161 (M⁺). HRMS calcd for C₇H₁₅NO₃ 161.1052, found 161.1088.

(3R,4R,5S)-N-tert-Butoxycarbonyl-3-(tert-butyldiphenylsilyloxy)-4-hydroxy-5-methylpiperidine (12). To a suspension of CuCN (135 mg, 1.5 mmol) in dry Et₂O (15 mL) at −78 °C was added a solution of MeLi (2.9 mL, 1.04 mol/L in Et₂O, 3 mmol) at −78 °C and the mixture was stirred under argon atmosphere at −78 °C for 10 min. The resulting solution was warmed to −10 °C then stirred for 30 min. The reaction mixture was cooled to −78 °C, and a solution of **9** (273 mg, 0.6 mmol) in dry Et₂O (15 mL) was added to the reaction mixture dropwise via syringe at −78 °C. The mixture was stirred at −78 °C for 10 min. BF₃·OEt₂ (4 mol/L in Et₂O, 3 mL, 1.2 mmol) was added to the reaction mixture at −78 °C and the solution was stirred for 2 h. The reaction mixture was quenched with 28% NH₄OH/sat. NH₄Cl (1:9) solution (30 mL) and stirred overnight at room temperature. The organic layer was separated and the aqueous layer was extracted with Et₂O (2 × 30 mL). The combined organic phases were washed with brine (20 mL), dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (*n*-hexane:AcOEt = 8:1) to give **12** (200 mg, 71%) as a colorless oil; [α]²³_D −16.7 (*c* 1.25, CHCl₃). ¹H NMR (600 MHz, CDCl₃) δ 0.97 (d, *J* = 6.6 Hz, 3H), 1.09 (s, 9H), 1.30 (s, 9H), 1.43 (br, 1H), 2.15−2.36 (m, 2H), 2.62 (dd, *J* = 12.5, 11.0 Hz, 1H), 3.18 (t, *J* = 9.0 Hz, 1H), 3.46−3.51 (m, 1H), 3.97 (br, 2H), 7.37−7.46 (m, 6H), 7.65−7.73 (m, 4H). ¹³C NMR (67.8 MHz, CDCl₃) δ 14.6, 19.3, 26.9, 28.2, 35.9, 48.7, 74.0, 79.6, 80.2, 127.9, 129.9, 133.3, 135.6, 154.2. IR (neat) (cm⁻¹) 3476, 1699. EI-MS (*m/z*) 470 (M⁺ + 1). HRMS calcd for C₂₇H₃₉NO₄Si 469.2649, found 469.2657.

(3R,4R,5S)-3,4-Dihydroxy-5-methylpiperidine (14, 5′-deoxyisofagomine). To a solution of **12** (141 mg, 0.30 mmol) in dioxane (2.5 mL) was added a solution of 10% HCl (10 mL), and the solution was heated at reflux for 1 h. After the reaction mixture was cooled to room temperature and diluted with H₂O (50 mL), the resultant dilute solution was washed with Et₂O (2 × 20 mL). The aqueous layer was concentrated under reduced pressure. The residue was dissolved in MeOH and made alkaline with Na₂CO₃. The mixture was filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (10% NH₄OH:MeOH = 1:50) to give **14** (37 mg, 92%) as a white powder; [α]²⁵_D +6.5 (*c* 0.5, EtOH). ¹H NMR (600 MHz, D₂O) δ 0.81 (d, *J* = 6.6 Hz, 3H), 1.36−1.44 (m, 1H), 2.09 (dd, *J* = 12.8, 11.7 Hz, 1H), 2.25 (dd, *J* = 12.1, 11.0 Hz, 1H), 2.76 (ddd, *J* = 13.1, 4.4, 1.5 Hz, 1H), 2.91 (t, *J* = 9.5 Hz, 1H), 2.97 (ddd, *J* = 12.3, 5.1, 1.6 Hz, 1H), 3.27−3.32 (m, 1H). ¹³C NMR (67.8 MHz, D₂O) δ 78.1, 71.2, 49.7, 49.0, 36.8, 13.1. EI-MS (*m/z*) 131 (M⁺). HRMS calcd for C₆H₁₃NO₂ 131.0946, found 131.0984.

(R)-N-tert-Butoxycarbonyl-5-(tert-butyldiphenylsilyloxy)-3-piperidene (ent-8). This compound was prepared from (−)-**3** (897 mg, 4.5 mmol), imidazole (511 mg, 7.5 mmol), DMAP (122 mg, 1 mmol), and *tert*-butylchlorodiphenylsilane (1.374 g, 5 mmol) according to the procedure described for the preparation of **8** to give *ent*-**8** (1.96 g, 99%); [α]²⁹_D −22.3 (*c* 1.40, CHCl₃).

(3S,4S,5S)-N-tert-Butoxycarbonyl-3-(tert-butyldiphenylsilyloxy)-4,5-epoxypiperidine (ent-9) and (3S,4R,5R)-N-tert-Butoxycarbonyl-3-(tert-butyldiphenylsilyloxy)-4,5-epoxypiperidine (ent-10). These compounds were prepared from *ent*-**8** (1.40 g, 3.2 mmol), 4 mmol/L of aq Na₂-EDTA (17.5 mL, 0.07 mmol), 1,1,1-trifluoroacetone (3.5 mL), NaHCO₃ (2.21 g, 26.25 mmol), and Oxone (10.73 g, 17.5 mmol) according to the procedure described for the preparation of **9** and **10** to give *ent*-**9** (1.04 g, 72%) and *ent*-**10** (272 mg, 19%).

ent-**9**: [α]³¹_D −29.7 (*c* 1.82, CHCl₃).

ent-**10**: [α]³⁰_D +6.9 (*c* 1.10, CHCl₃).

(3S,4S,5R)-N-tert-Butoxycarbonyl-3-(tert-butyldiphenylsilyloxy)-4-hydroxy-5-vinylpiperidine (ent-11). This compound was prepared from *ent*-**9** (454 mg, 1 mmol), *n*-BuLi (3.125 mL, 1.6 M in *n*-hexane, 5 mmol), tetravinyltin (1.14 g, 5 mmol), CuCN (224 mg, 2.5 mmol), and BF₃·OEt₂ (4 mol/L in Et₂O, 5 mL, 2 mmol) according to the procedure described for the preparation of **11** to give *ent*-**11** (383 mg, 80%); [α]³⁰_D +10.6 (*c* 1.00, CHCl₃).

(3S,4S,5S)-3,4-Dihydroxy-5-(hydroxymethyl)piperidine (15). This compound was prepared from *ent*-**11** (241 mg, 0.5 mmol), 4% OsO₄ (164 μL, 0.025 mmol), NaIO₄ (238 mg, 1.1 mmol), and NaBH₄ (95 mg, 2.5 mmol) according to the procedure described for the preparation of **2** to give (3*S*,4*S*,5*S*)-*N*-*tert*-butoxycarbonyl-3-(*tert*-butyldiphenylsilyloxy)-4-hydroxy-5-(hydroxymethyl)piperidine (216 mg, 89%); [α]³⁰_D +15.5 (*c* 1.16, CHCl₃). This compound was prepared from *ent*-**8** (131 mg, 0.27 mmol) according to the procedure described for the preparation of **2** to give **15** (38 mg, 96%); [α]²⁴_D −23.8 (*c* 1.10, EtOH).

(3S,4S,5R)-3,4-Dihydroxy-5-(hydroxyethyl)piperidine (16). This compound was prepared from *ent*-**11** (121 mg, 0.5 mmol), 9-BBN (0.5 mol/L in THF, 2.5 mL, 1.25 mmol), 3 mol/L of aq NaOH (1 mL), and 30% aq H₂O₂ (1 mL) according to the procedure described for the preparation of **13** to give (3*S*,4*S*,5*R*)-*N*-*tert*-butoxycarbonyl-3-(*tert*-butyldiphenylsilyloxy)-4-hydroxy-5-(hydroxyethyl)piperidine (113 mg, 91%); [α]²³_D +5.3 (*c* 1.35, CHCl₃). This compound was prepared from the diol (90 mg, 0.18 mmol) according to the procedure described for the preparation of **13** to give **16** (28 mg, 97%); [α]²⁵_D −17.8 (*c* 1.13, EtOH).

(3S,4S,5R)-N-tert-Butoxycarbonyl-3-(tert-butyldiphenylsilyloxy)-4-hydroxy-5-methylpiperidine (ent-12). This compound was prepared from *ent*-**9** (182 mg, 0.4 mmol), MeLi (2.4 mL, 1.04 mol/L in Et₂O, 2.5 mmol), CuCN (112 mg, 1.25 mmol), and BF₃·OEt₂ (4 mol/L in Et₂O, 2.5 mL, 1 mmol)

according to the procedure described for the preparation of **12** to give *ent*-**12** (133 mg, 71%); [α]$^{25}_D$ +17.2 (*c* 1.03, CHCl$_3$).

(3S,4S,5R)-3,4-Dihydroxy-5-methylpiperidine (17). This compound was prepared from *ent*-**12** (127 mg, 0.27 mmol) according to the procedure described for the preparation of **3** to give **17** (34 mg, 96%); [α]$^{25}_D$ −7.4 (*c* 0.90, EtOH).

(3S,5S)-*tert*-Butyl 3,4,5-Trihydroxypiperidine-1-carboxylate (22) and (3R,4s,5S)-*tert*-Butyl 3,4,5-trihydroxypiperidine-1-carboxylate (23). To a solution of *ent*-**8** (219 mg, 0.5 mmol) in acetone (2 mL) was added an aqueous 4% OsO$_4$ solution (65 µL, 0.01 mmol). After 10 min, an aqueous 50% NMO solution (176 mL, 0.75 mmol) was added and the mixture was stirred overnight. To the solution were added Na$_2$SO$_3$ and Na$_2$SO$_4$. The mixture was filtered through a Celite pad and the filtrate was evaporated. The residue was chromatographed on silica gel (*n*-hexane:AcOEt = 1:1) to give a diastereoisomeric mixture of *N-tert*-butoxycarbonyl-5-*tert*-butyldiphenylsilyloxy-3,4-dihydroxypiperidine (236 mg, 99%). To a solution of the above diol (513.8 mg, 1.09 mmol) in THF (10 mL) was added 1 M TBAF (2,2 mL, 2.2 mmol) in THF at room temperature. After being stirred overnight, sat. K$_2$CO$_3$ (5 mL) was added and the reaction mixure was extracted with CHCl$_3$. The aqueous layer was extracted with CHCl$_3$. The combined organic solvents were dried over MgSO$_4$ and evaporated. The residue was chromatographed on silica gel (CHCl$_3$:MeOH = 1:1) to give **23** (7.4 mg, 3%) and **22** (189 mg, 74%). **22**: [α]$^{22}_D$ +24.5 (*c* 1.74, CHCl$_3$); ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.44 (9H, s), 2.57 (1H, br s), 2.73 (1H, br s), 3.01 (1H, d, *J* = 12.4 Hz), 3.50 (1H, d, *J* = 7.1 Hz), 3.83 (1H, br s), 3.98−4.05 (3H, m), 4.21−4.43 (1H, m). ^{1}H NMR (400 MHz, CD$_3$OD) δ 1.45 (9H, s), 2.97, 3.12 (1H, br s), 3.30 (2H, dd, *J* = 3.2, 1.7 Hz), 3.52−3.86 (4H, m). ^{13}C NMR (100 MHz, CDCl$_3$) δ 28.4, 29.7, 47.7, 67.5, 67.9, 74.9, 80.5, 156.0. IR (KBr) (cm^{-1}) 3371 (−OH), 2966, 2932, 2876, 1682 (C=O), 1462, 1428, 1366, 1246, 1168, 1073. EI-MS (*m/z*) 233 (M$^+$). HRMS calcd for C$_{10}$H$_{19}$NO$_5$ 233.1263, found 233.1242.

23: ^{1}H NMR (400 MHz, CDCl$_3$) δ 1.45 (9H, s), 3.28 (2H, d, *J* = 13.2 Hz), 3.74−4.28 (7H, m). ^{1}H NMR (400 MHz, CD$_3$OD) δ 1.45 (9H, s), 3.16 (1H, br s), 3.29−3.65 (5H, m), 3.85−3.86 (1H, m). ^{13}C NMR (100 MHz, CDCl$_3$) δ 28.3, 46.0, 68.8, 70.3, 80.5, 155.9. IR (KBr) (cm^{-1}) 3416 (−OH), 2929, 1693 (C=O), 1540, 1464, 1416, 1367, 1325, 1264, 1232, 1168, 1076, 1017. EI-MS (*m/z*) 233 (M$^+$). HRMS calcd for C$_{10}$H$_{19}$NO$_5$ 233.1263, found 233.1286.

(3S,5S)-Piperidine-3,4,5-triol (18). A solution of **22** (179.5 mg, 0.38 mmol) in dioxane (1 mL) and 10% HCl (4 mL) was refluxed for 1 h. Et$_2$O (10 mL) was added to the solution and the mixture was separated. The organic layer was extracted with water and the combined aqueous layers were concentrated to yield the hydrochloride of **18** as a solid. The solid was purified by ion-exchange resin (Amberlite IRA-410, OH$^-$) to give the free amine **18** (49.6 mg, 98%).

18-HCl: mp 198−199 °C [lit.^{25c} mp 195.5−196 °C]. [α]$^{25}_D$ +20.8 (*c* 1.4, CH$_3$OH), [lit.^{25c} [α]$^{20}_D$ +22.7 (*c* 0.8, CH$_3$OH)]. ^{1}H NMR (400 MHz, D$_2$O) δ 2.93 (1H, dd, *J* = 12.7, 8.5 Hz), 3.18 (1H, dd, *J* = 12.9, 1.7 Hz), 3.27 (1H, dd, *J* = 12.9, 5.9 Hz), 3.31 (1H, dd, *J* = 12.7, 3.9 Hz), 3.75 (1H, dt, *J* = 7.7, 1.3 Hz), 4.04−4.09 (1H, m), 4.21 (1H, ddd, *J* = 5.9, 2.7, 1.7 Hz). ^{13}C NMR (67.8 MHz, D$_2$O, reference acetone δ 30.3) δ 45.5, 46.1, 64.7, 65.0, 70.8. IR (KBr) (cm^{-1}) 3343 (−OH), 3088, 2904, 2852, 1610, 1475, 1441, 1408, 1368, 1339, 1306, 1271, 1227, 1208, 1099, 1079, 1056. EI-MS (*m/z*) 133 (M$^+$). HRMS calcd for C$_5$H$_{11}$NO$_3$ 133.0739, found 133.0730.

18: [α]$^{20}_D$ +65.8 (*c* 0.9, CH$_3$OH) [lit.^{23} [α]$_D$ +66.7 (*c* 0.3, CH$_3$OH)]. ^{1}H NMR (400 MHz, D$_2$O) δ 2.31 (1H, dd, *J* = 12.9, 9.5 Hz), 2.62 (1H, dd, *J* = 14.1, 2.0 Hz), 2.82 (1H, dd, *J* = 13.9, 3.4 Hz), 2.96 (1H, dd, *J* = 13.7, 4.4 Hz), 3.45 (1H, dd, *J* = 8.5, 3.2 Hz), 3.67 (1H, dt, *J* = 9.0, 4.6 Hz), 3.87 (1H, m). ^{13}C NMR (100 MHz, D$_2$O, reference acetone δ 30.3) δ 47.4, 47.5, 67.2, 67.3, 72.8. IR (neat) (cm^{-1}) 3388 (−OH), 2928, 2364, 2344, 1736, 1720, 1656, 1640, 1561, 1545, 1452, 1345, 1274, 1072.

EI-MS (*m/z*) 133 (M$^+$). HRMS calcd for C$_5$H$_{11}$NO$_3$ 133.0739, found 133.0739.

(3R,5R)-Piperidine-3,4,5-triol (21). The piperidinetriol **21** was prepared from **8** according to the same procedure described for **18**, via *ent*-**22**.

ent-**22**: (79%); [α]$^{28}_D$ −25.0 (*c* 1.33, CHCl$_3$).

21-HCl: [α]$^{25}_D$ −20.7 (*c* 1.1, CH$_3$OH) [lit. ^{25c} [α]$^{20}_D$ −22 (*c* 0.8, CH$_3$OH)].

21: (98%); [α]$^{20}_D$ −66.0 (*c* 1.2, CH$_3$OH).

(3R,4s,5S)-*tert*-Butyl 3,4,5-trihydroxypiperidine-1-carboxylate (23) and (±)-22. A solution of OsO$_4$ (254.2 mg, 1 mmol) in CH$_2$Cl$_2$ (1 mL) was added to a solution of (±)-**3** (199 mg, 1 mmol) and TMEDA (116 mg, 1 mmol) in CH$_2$Cl$_2$ (22 mL) at −78 °C. The mixture was stirred at the same temperature for 2 h, warmed to room temperature, and stirred for 2 h. The reaction mixture was evaporated. The resulting residue was dissolved in MeOH (10 mL). Hydrochloric acid (conc 7 drops) was then added and the solution was stirred for 2 h at room temperature. The reaction mixture was concentrated under reduced pressure. The residue was redissolved in MeOH (15 mL) and Et$_3$N (202 mg, 2 mmol) and Boc$_2$O (262 mg, 1.2 mmol) were added to the resulting mixture. The reaction mixture was stirred at room temperature overnight and then evaporated. The residue was purified by chromatography on silica gel (CHCl$_3$:MeOH = 10:1) to give **23** (153 mg, 66%) and (±)-**22** (38 mg, 16%).

(3R,4s,5S)-Piperidine-3,4,5-triol (19). A solution of **23** (179.5 mg, 0.38 mmol) in dioxane (1 mL) and 10% HCl (4 mL) was refluxed for 1 h. Et$_2$O (10 mL) was added to the solution and the mixture was separated. The organic layer was extracted with water and the combined aqueous layers were concentrated to yield the hydrochloride of **19** as a solid. The solid was purified by ion-exchange resin (Amberlite IRA-410, OH$^-$) to give the free amine **19** (42.5 mg, 84%).

19-HCl: mp 182−184 °C [lit.^{25c} mp 185−187 °C]. ^{1}H NMR (400 MHz, D$_2$O) δ 3.10−3.15 (4H, m), 3.92−3.97 (3H, m). ^{13}C NMR (100 MHz, D$_2$O, reference acetone δ 30.3) δ 44.1, 65.5, 68.3. IR (KBr) (cm^{-1}) 3435 (−OH), 2944, 2824, 2674, 2568, 1582, 1465, 1439, 1415, 1339, 1320, 1255, 1190, 1117, 1094. EI-MS (*m/z*) 133 (M$^+$). HRMS calcd for C$_5$H$_{11}$NO$_3$ 133.0739, found 133.0764.

19: mp 163−165 °C. ^{1}H NMR (400 MHz, D$_2$O) δ 2.57 (2H, d, *J* = 9.0 Hz), 2.64 (2H, dd, *J* = 12.7, 4.4 Hz), 3.58−3.62 (2H, m), 3.86 (1H, s). ^{13}C NMR (100 MHz, D$_2$O, reference acetone δ 30.3) δ 44.9, 68.6, 70.6. IR (KBr) (cm^{-1}) 3390 (−OH), 3285, 2930, 1866, 1842, 1790, 1456, 1041. EI-MS (*m/z*) 133 (M$^+$). HRMS calcd for C$_5$H$_{11}$NO$_3$ 133.0739, found 133.0715.

(3S,5S)-Piperidine-3,4,5-triol (20). A mixture of (±)-**9** (436 mg, 0.96 mmol) in dioxane (6 mL), H$_2$O (4 mL), and concentrated H$_2$SO$_4$ (0.64 mL) was heated at 95 °C for 3 h. The reaction mixture was concentrated and the residue was purified by ion-exchange resin (Amberlite IRA-410, OH$^-$) to give the free amines **20** (69.7 mg, 55%) and (±)-**18** (26.0 mg, 20%).

20: mp 160−162 °C. ^{1}H NMR (400 MHz, D$_2$O) δ 2.23 (2H, dd, *J* = 12.7, 0.7 Hz), 2.93 (2H, dd, *J* = 12.4, 4.9 Hz), 3.12 (2H, dt, *J* = 16.1, 2.2 Hz), 3.29−3.36 (1H, m). ^{13}C NMR (270 MHz, D$_2$O, reference acetone δ 30.3) δ 49.3, 71.0, 78.4. IR (KBr) (cm^{-1}) 3405 (−OH), 3308, 2976, 2909, 2860, 2690, 1654, 1457, 1365, 1337, 1286. EI-MS (*m/z*) 133 (M$^+$). HRMS calcd for C$_5$H$_{11}$NO$_3$ 133.0739, found 133.0728.

Supporting Information Available: Copies of ^{1}H NMR and ^{13}C NMR spectra of all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

JO050519J